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Cyr, Me´lanie, Yves Lepage, Charles Blais, Jr., Nicole
Gervais, Massimo Cugno, Jean-Lucien Rouleau, and
Albert Adam. Bradykinin and des-Arg9-bradykinin meta-
bolic pathways and kinetics of activation of human plasma.
Am J Physiol Heart Circ Physiol 281: H275–H283, 2001.—In
the serum of 116 healthy individuals, exogenous bradykinin
(BK) half-life (27 6 10 s) was lower than that of des-Arg9-BK
(643 6 436 s) and was statistically different in men compared
with women. The potentiating effect of an angiotensin-
converting enzyme (ACE) inhibitor was, however, more
extensive for BK (9.0-fold) than for des-Arg9-BK (2.2-
fold). The activities of ACE, aminopeptidase P (APP), and
kininase I were respectively 44 6 12, 22 6 9, and 62 6 10
nmol zmin21 zml21. A mathematical model (y 5 ktae2bt, t .
0), applied to the BK kinetically released from endogenous
high-molecular-weight kininogen (HK) during plasma acti-
vation in the presence of an ACE inhibitor, revealed a signif-
icant difference in the rate of formation of BK between men
and women. For des-Arg9-BK, the active metabolite of BK,
the rate of degradation was higher in women compared with
men, correlating significantly with serum APP activity (r2 5
0.6485, P , 0.001). In conclusion, these results constitute a
basis for future pathophysiological studies of inflammatory
processes where activation of the contact system of plasma
and the kinins is involved.
kinins; angiotensin-converting enzyme inhibitors; contact
system activation
BRADYKININ (BK) is a nonapeptide released from high-
molecular-weight kininogen (HK) under hydrolysis by
plasma kallikrein. Plasma kallikrein originates from
prekallikrein during the activation of the contact sys-
tem of plasma by a negatively charged surface (3). This
activation has been considered for a long time as the
unique mechanism leading to BK release. Recently,
however, three different laboratories (10, 23, 35) have
described HK activation by plasma kallikrein at the
endothelial level.
BK exerts its pharmacological effects, mainly vaso-
dilation, by activating constitutively expressed B2 re-
ceptors. However, the peptide is short-lived in various
biological environments due to proteolytic cleavage.
The different purified peptidases capable of degrading
BK have been reviewed extensively (15). The impor-
tance of their participation in BK metabolism depends,
however, on the nature of the biological milieu as well
as the pathophysiological or experimental conditions
(5, 15). Previously, the laboratory of Adam (13) devel-
oped an analytic approach that allowed the metabolism
of exogenous BK to be measured in a limited number of
human serum samples using the substrate at a nano-
molar concentration. Adam and co-workers showed
that BK is metabolized by three metallopeptidases.
Angiotensin-converting enzyme (ACE) constitutes the
main degradation pathway that transforms BK into its
final inactive metabolite BK(1–5) (13, 15). The next
most important enzyme is aminopeptidase P (APP),
which transforms BK into the inactive peptide BK(2–
9) (6). This metabolite is further degraded by dipepti-
dyl peptidase IV into BK(4–9) (6). Finally, kininase I, a
generic name for different carboxypeptidases that
transform BK into des-Arg9-BK (15), constitutes a mi-
nor metabolic pathway unless ACE is inhibited. Des-
Arg9-BK, the active metabolite of BK, stimulates B1
receptors when expressed during experimental inflam-
matory conditions (4, 25, 26). In its turn, des-Arg9-BK
is metabolized by ACE and APP, already involved in
BK inactivation. However, in the case of des-Arg9-BK,
APP represents the main metabolic pathway (6).
Because ACE has a higher affinity for BK than for
angiotensin I (21, 22), it is now considered as a kini-
nase rather than an angiotensinase (9, 21, 22). These
kinetic characteristics and numerous experimental
pieces of evidence, mainly of a pharmacological nature,
plead for a role of BK in the cardiovascular and meta-
bolic effects of ACE inhibitors (18, 24, 40). Besides
these beneficial effects, ACE inhibitors are also en-
dowed with acute and chronic side effects, among
which are angioedema (AE), hypersensitivity reactions
(HSR) during hemodialysis, severe hypotensive reac-
tion (SHR) associated with some blood product trans-
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fusions, and cough (16, 20, 42). Although BK has been
claimed to be responsible for these side effects, its
participation has been scarcely documented, and only
poor experimental evidence, if any, suggests such a
pathophysiological role for the B2 agonist. To try to
elucidate a potential role of kinins in the pathophysi-
ology and symptoms of these acute and chronic side
effects of ACE inhibitors, we (6, 7, 11) investigated BK
metabolism in the serum of a limited number of pa-
tients who presented such side effects. Patients with a
history of an HSR or a SHR associated with an ACE
inhibitor exhibited, at the serum level, an increased
half-life (t½) of des-Arg9-BK, this kinetic parameter
correlating negatively with the APP activity.
The fact that the decreased activity of APP was not
attributed to a circulating inhibitor but rather to an
enzyme defect (6) required definition of the metabolism
of kinins in normal individuals before extending these
preliminary studies to larger groups of patients and
their relatives who developed ACE inhibitor complica-
tions such as AE, HSR, or SHR.
In the present paper, we defined the metabolic pro-
file of BK and its active metabolite, des-Arg9-BK, in a
large number of healthy individuals (men and women)
to obtain reference values. To accomplish these goals,
we first applied to these samples the experimental
approach we developed previously for a small number
of men (n 5 7) (13). The calculated kinetic parameters
were verified by the measurement of metallopeptidase
activities (ACE, APP, and kininase I) responsible for
the serum metabolism of kinins. In a second part, the
kinetics of generation of endogenous BK and des-
Arg9-BK from HK were assessed when the contact
system was activated by glass beads in the presence of
an ACE inhibitor. Finally, comparisons were made
between the results obtained by the different analyti-
cal approaches.
MATERIALS AND METHODS
Blood Samples
Twenty milliliters of blood were obtained by venipuncture
from the forearm of 116 healthy Caucasian volunteers (70
women and 46 men: 78 with were ,40 yr old and 38 were
$40 yr old) who were not under any medication (mean age:
33 6 14 yr, range 19–77 yr). Total blood was collected half
into dry tubes and the other half into tubes containing 0.1
mol/l sodium citrate as anticoagulant (1 volume of sodium
citrate to 9 volumes of blood). After centrifugation (22°C, 15
min, 2,500 g), the serum and plasma samples were decanted
and stored at 220°C until biochemical investigation.
This study was reviewed and approved by the ethics com-
mittee for research on human subjects of the Universite´ de
Montre´al.
Drugs, Peptides, and Reagents
BK and des-Arg9-BK were obtained from Peninsula Labo-
ratories (Belmont, CA). The ACE inhibitor enalaprilat was
from Merck Frosst Canada (Kirkland, QC, Canada). L-Argi-
nine, dansyl-Ala, and o-phthalaldehyde were from Sigma-
Aldrich (Oakville, ON, Canada). Arg-Pro-Pro was from
Bachem (Torrance, CA). Dansyl-Ala-Arg was a generous gift
from Dr. R. A. Skidgel (Dept. of Pharmacology, University of
Illinois, College of Medicine, Chicago, IL). b-Mercaptoethanol
and chloroform were purchased from Fisher Scientific (Mon-
tre´al, QC, Canada). HPLC grade ethanol was procured from
American Chemicals (Montre´al, QC, Canada).
Metabolism of Exogenous BK and Des-Arg9-BK
Incubation procedure. A first set of incubations was per-
formed to assess the metabolic profile of exogenous BK in the
absence of in vitro ACE inhibition. Synthetic BK was added
to the serum samples (final concentration of the peptide 5
471 nM) (13). After various incubation periods at 37°C, rang-
ing from 30 s to 120 min, the reaction was stopped by adding
cold anhydrous ethanol at a final concentration of 80% vol/
vol. The samples were then incubated at 4°C for 1 h and
centrifuged (4°C, 15 min, 3,000 g) for the complete precipita-
tion of kinin precursors. The supernatant was decanted and
evaporated to dryness in a Speed Vac Concentrator (Savant;
Farmingdale, NY). The residues were stored at 220°C until
quantification of the immunoreactive peptides BK and des-
Arg9-BK was performed.
A second set of incubations was undertaken to define the
influence of complete in vitro inhibition of ACE on BK me-
tabolism. Serum was preincubated at 37°C for 20 min with
enalaprilat (final concentration 5 130 nM) before the addi-
tion of exogenous BK. This solution was then incubated and
treated in the same manner as described above.
Quantification of BK and des-Arg9-BK. The residues of the
evaporated ethanolic extracts were resuspended in 50 mM
Tris zHCl buffer, pH 7.4, containing 100 mM NaCl and 0.05%
Tween 20. After resuspension, residual BK and formed des-
Arg9-BK were quantified by two specific competitive chemi-
luminescent enzyme immunoassays, as previously described
(12, 32). To detect and quantify immune complexes, both
assays used highly specific polyclonal rabbit immunoglobu-
lins raised against the carboxy-terminal end of BK and des-
Arg10-kallidin and the digoxigenin-anti-digoxigenin system
(Boehringer Mannheim; Laval, QC, Canada). These methods
have been validated, and their analytic performances were
reported (4, 8, 12, 32).
Kinetic parameters. The kinin (S) hydrolysis rate constant
(k) was obtained with a first-order equation S 5 So 3 e2kt. t1⁄2
was calculated as t1⁄2 5 ln(2)/k (28).
The hydrolysis constant rate without [k(2)] or with [k(1)]
enalaprilat served to estimate ACE relative activity
(ACE%) 5 100 3 [12k(1)/k(2)]. The relative participation of
kininase I in BK metabolism in the absence or the presence
of an ACE inhibitor was expressed as the percentage of added
BK transformed into des-Arg9-BK.
Serum Metallopeptidase Activity Measurement
Serum ACE activity. ACE activity in serum samples was
determined by Buhlmann ACE radioenzymatic assay (Angio-
tensin-Converting Enzyme 3H-REA, ALPCO; Windham, NH)
according to the manufacturer’s instructions. This assay
measured the hydrolysis of the synthetic substrate [3H]hip-
puryl-glycyl-glycine into [3H]hippuric acid and a dipeptide,
solvent extraction separated tritiated hippuric acid from the
unreacted substrate, and radioactivity was measured in a
beta counter. For each sample, tests were performed in du-
plicate. ACE activity was expressed as ACE units, as de-
scribed by the manufacturer (1 unit ACE 5 1 nmol of formed
[3H]hippuric acid zmin21 zml21).
Serum APP activity. APP activity was measured in serum
samples by a modified version of the assay described earlier
by Blais et al. (6) and Simmons and Orawski (36). Briefly, 20
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ml of serum were incubated with Arg-Pro-Pro (final concen-
tration 5 0.5 mM) in 0.1 M HEPES buffer, pH 7, for a final
volume of 200 ml. After an incubation period of 6 h at 37°C,
the reaction was stopped by adding cold anhydrous ethanol
(800 ml). The samples were then centrifuged (4°C, 15 min,
3,000 g), and the supernatant was decanted and incubated at
room temperature (between 10 and 30 min) with 3 ml of the
revelation buffer (0.05 M borate buffer, pH 9.5, containing
150 mg/l o-phthalaldehyde and 50 ml/l b-mercaptoethanol).
Fluorescence emission was read on an Aminco-Bowman Lu-
minescence Spectrometer (Rochester, NY). The excitation
and emission wavelengths were 310 and 455 nm, respec-
tively. The emission intensity of a calibration curve with
L-arginine (0 to 5 mM) was obtained under the same condi-
tions. The results are expressed as nanomoles of arginine
released per minute per milliliter of serum sample.
Serum kininase I activity. Kininase I activity was mea-
sured by a modification of the method described by R. A.
Skidgel (37). Briefly, 20 ml of serum were incubated at 37°C,
for 70 min, with dansyl-Ala-Arg (final concentration: 0.2 mM)
in 0.1 M HEPES buffer, pH 7 (total volume: 250 ml). After the
incubation period, the reaction was stopped by adding citric
acid 1 M (150 ml). Dansyl-Ala was extracted (15 s) by 3 ml of
chloroform. After centrifugation (4°C, 10 min, 1,000 g) and
removal of the aqueous phase, the fluorescence of the organic
phase was measured, as described for APP, using 340 and
495 nm, respectively, as excitation and emission wave-
lengths. The emission intensity of a calibration curve (dan-
syl-Ala, 0 to 1 mM) was determined under the same condi-
tions. The results are expressed as nanomoles of dansyl-Ala
released per minute per milliliter of serum sample.
Kinetics of Release of Endogenous BK and Des-Arg9-BK
During Plasma Activation
Contact system activation. After 1 ml of plasma was pre-
incubated with enalaprilat (final concentration 5 130 nM) for
20 min at 37°C in polypropylene tubes, the contact system
was activated by incubating the plasma with glass beads
(37°C, with agitation), using a modification of the method of
Renaux et al. (33). The reaction was stopped after various
incubation periods (0, 1, 2, 3, 4, 6, 12, 24, 36, 60 min for BK
and 0, 3, 6, 12, 18, 24, 36, 48, 60, 120 min for des-Arg9-BK) by
adding cold anhydrous ethanol at a final concentration of
80% vol/vol. The samples were then treated as described
above for the metabolism of exogenous kinins before the
quantification of endogenous BK and des-Arg9-BK.
Mathematical treatment. For the endogenous measure-
ments obtained at different times t, the mathematical model
y 5 ktae2bt, t . 0, was fitted to each subjects. This model with
three parameters k, a, and b (k . 0, a $ 0, b $ 0) corresponds
to a form similar to gamma distribution (34). Parameter k
represents a scale parameter: large (small) k values are for
large (small) values of the endogenous measurements. When
a is small (large), the speed in obtaining the maximum is fast
(slow), whereas for small (large) values of b, the speed at
which the curve decreases to 0 is slow (fast). Parameter a is
therefore related to the shape of the first part of the curve
(the part that corresponds to formation), whereas parameter
b is related to the second part of the curve, corresponding to
the degradation.
To study the various curves, different functions of the
parameters were calculated. 1) Time of the maximum: the
value of time t for which the maximum of the curve was
obtained t 5 a/b; 2) maximum: the value of the maximum of
the curve that corresponds to the value of the curve for t 5
a/b; 3) the area: area under the curve that is mathematically
given by kG(a 1 1)/ba 1 1, where G(a 1 1) is the gamma
function; 4) half-life of formation (tf): the value tf in the
interval 0 to a/b for which tae2bt 5 (0.5) (a/b)ae2a; 5) half-life
of degradation (td): the value td in the interval a/b to ‘ for
which tae2bt 5 (0.5) (a/b)ae2a; 6) slope of the half-life of
formation: the value of the slope of the curve at half-life
formation 5 kef2bt t fa21(a 2 btf); and 7) slope of the half-life
of degradation: the value of the slope of the curve at half-life
degradation: ke2bt tda21(a 2 btd).
Statistical Analysis
All data are expressed as means 6 SD. Two-way analysis
of variance was performed to study the effect of sex (men and
women) and age (,40 yr and $40 yr) on the variables and the
parameters of the mathematical model (29). When significant
results were observed, a Satterwaite-Welch approach (30)
was used to test the possible effect of the heterogeneity of
variances on the P value. A P value , 0.05 was considered
significant. Reference limits were determined nonparametri-
cally by using the conventional empirical 2.5 and 97.5 per-
centiles. Pearson correlation and simple linear regression
were used to study the linear relationship between certain
variables (31).
RESULTS
Metabolism of Exogenous BK and Des-Arg9-BK
Half-life of BK and des-Arg9-BK. The t1⁄2 of BK and
des-Arg9-BK, in the absence and presence of enalapri-
lat, in 116 healthy individuals is presented in Table 1.
In the absence of ACE inhibition, BK was rapidly
degraded (t1⁄2 5 27 6 10 s). This value contrasted with
the t1⁄2 of des-Arg9-BK, which was 24 times higher
(mean value 643 6 436 s). When serum samples were
preincubated with enalaprilat at a concentration that
completely inhibited ACE activity, the t1⁄2 of BK and
des-Arg9-BK was increased (244 6 83 s and 1,410 6
1,149 s, respectively). The potentiating effect of enala-
prilat was more pronounced in the case of BK, t1⁄2 being
increased by 9.0-fold compared with 2.2-fold for des-
Arg9-BK. The mean values for des-Arg9-BK t1⁄2 (in the
absence and presence of enalaprilat) presented ele-
vated SD due to the wide ranges of t1⁄2 without (196 to
2,878 s) and with (330 to 6,704 s) enalaprilat.
For the t1⁄2 of BK and des-Arg9-BK without and with
enalaprilat, no significant interaction between sex and
age was observed and the factor age was not signifi-
cant. For the factor sex, only the t1⁄2 of BK (in the
absence of enalaprilat) was significantly lower in men
compared with women (24 6 8 vs. 30 6 11 s, P 5
0.0030).
Relative participation of ACE and kininase I in the
metabolism of kinins. The relative contributions of the
various metallopeptidases in the degradation of BK
and des-Arg9-BK in human serum are shown in Table
1. ACE constituted the main enzyme responsible for
the BK inactivation accounting for 88 6 6% of total BK
metabolic transformation. Also, this relative participa-
tion of ACE in BK metabolism showed no significant
sex-to-age interaction and age effect but was statisti-
cally higher in men than in women (90 6 3%, n 5 46 vs.
87 6 7%, n 5 70, P 5 0.027). Kininase I participation
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in BK metabolism is minor (11 6 5%) but became more
pronounced (46 6 23%) when ACE was inhibited. In
the case of des-Arg9-BK, ACE represented only 50 6
12% of total degrading activity. The relative participa-
tion of both metallopeptidases in the serum metabo-
lism of kinins showed no significant sex-to-age interac-
tion and was not statistically different between both
sexes and both categories of age.
Serum metallopeptidase activities. The values ob-
tained for serum ACE, APP, and kininase I are pre-
sented in Table 2. For each of these serum activities, no
significant interaction sex-to-age was observed, and
the factor age was not significant. The difference in
ACE activity was highly significant between men (n 5
46) and women (n 5 70) (49 6 13 vs. 41 6 11
nmol zmin21 zml21, P 5 0.0097). Similarly, significantly
higher serum APP activity was measured in women
(24 6 9 nmol zmin21 zml21, n 5 70) compared with men
(19 6 7 nmol zmin21 zml21, n 5 46) (P 5 0.0292). In
contrast, kininase I exhibited similar values in both
groups of men and women (60 6 10 vs. 63 6 11
nmol zmin21 zml21 for men and women, respectively).
Reference intervals. Reference intervals for all vari-
ables (t1⁄2 of BK with and without enalaprilat, t1⁄2 of
des-Arg9-BK in the presence or absence of enalaprilat,
relative participation of ACE and kininase I in the
serum metabolism of BK and des-Arg9-BK and serum
ACE, APP, and kininase I activities) were determined
in 116 healthy individuals and are shown in Table 3.
When significant differences between men and women
Table 1. Half-life of BK and des-Arg9-BK with or without enalaprilat and the relative participation of ACE
and kininase I in the metabolism of kinins in the sera of 116 healthy individuals
t1⁄2, s
BK Des-Arg9-BK
Without enalaprilat With enalaprilat Without enalaprilat With enalaprilat
27610 244683 6436436 1,41061,149
Men Women Men Women Men Women Men Women
2468* 30611* 240680 246686 7326417 5846442 1,60061,182 1,28561,118
,40 y $40 y ,40 y $40 y ,40 y $40 y ,40 y $40 y
2769 28612 238685 255679 7006478 5256308 1,56461,280 1,0936737
Relative Participation of ACE and Kininase I, %
BK Des-Arg9-BK
% ACE % Kininase I % Kininase I1enalaprilat % ACE
8866 1165 46623a 50612
Men Women Men Women Men Women Men Women
9063† 8767† 1165 1265 49622b 45623c 50613 51612
,40 y $40 y ,40 y $40 y ,40 y $40 y ,40 y $40 y
8865 8867 1265 1065 49623d 42622e 51622 50612
Values are means 6 SD (men, n 5 46; women, n 5 70; ,40 y, n 5 78; $40 y, n 5 38; an 5 110; bn 5 43; cn 5 67; dn 5 75; en 5 35
individuals). BK, bradykinin; ACE, angiotensin-converting enzyme; t1⁄2, half-life. *P 5 0.0030; †P 5 0.0266.
Table 2. Enzyme activities of ACE, APP, and
kininase I in the serum of 116 healthy individuals
ACE,
nmol zmin21 zml21
APP,
nmol zmin21 zml21
Kininase I,
nmol zmin21 zml21
44612 2269 62610
Men Women Men Women Men Women
49613* 41611* 1967† 2469† 60610 63611
,40 y $40 y ,40 y $40 y ,40 y $40 y
44611 44614 2169 23610 61611 62610
Values are means 6 SD (men, n 5 46; women, n 5 70; ,40 y,
n 5 78; $40 y, n 5 38). APP, aminopeptidase. *P 5 0.0006; †P 5
0.0033.
Table 3. Distribution of variables in a healthy
population
Variable
Total
Population
(n 5 116)
Men
(n 5 46)
Women
(n 5 70)
t1⁄2 BK, s
Without enalaprilat 15–53 15–41 15–54
With enalaprilat 123–478
t1⁄2 des-Arg9-BK, s
Without enalaprilat 236–1,901
With enalaprilat 468–4,473
Relative participation of ACE
and kininase I for BK
% ACE 68–95 83–94 68–95
% kininase I 4–22
% kininase I1enalaprilat
for des-Arg9-BK
9–91
% ACE 27–72
Serum enzymatic activities
ACE, nmol zmin21 zml21 23–69 26–72 23–63
APP, nmol zmin21 zml21 7–39 7–30 7–39
Kininase I,
nmol zmin21 zml21 38–80
Data are reference intervals (2.5–97.5 percentiles of each distri-
bution).
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were observed, that is, for the variables t1⁄2 of BK in the
absence of enalaprilat, the relative participation of
ACE in the metabolism of BK, ACE, and APP activities
(see Tables 1 and 2). Separate reference intervals for
men and women are presented in Table 3.
Correlation between kinetic parameters and enzyme
activities. Table 4 shows the correlation between serum
enzymatic activities (ACE and APP) and the t1⁄2 of BK
and des-Arg9-BK in the absence and presence of ena-
laprilat. As expected, a significant inverse relationship
could be calculated between the measured t1⁄2 of BK in
the absence of ACE inhibition and ACE activity (r 5
20.6677, P 5 0.0001). Also, significant correlations
could be calculated between serum APP activity and
the calculated t1⁄2 of BK in the presence and absence of
enalaprilat (r 5 20.5206, P 5 0.0001 and r 5 20.2433,
P 5 0.0085, respectively) and the t1⁄2 of des-Arg9-BK in
the absence (r 5 20.6924, P 5 0.0001) and presence
(r 5 20.6840, P 5 0.0001) of enalaprilat. In addition,
the relationship between serum APP activity and the
relative contribution of ACE in BK metabolism was
also significant (r 5 20.6403, P 5 0.0001) (data not
shown).
Metabolism of Endogenous BK and Des-Arg9-BK
Analysis of the influence of the factors sex and age on
the different parameters characterizing the gamma
model fitted to endogenous measures in time are
showed in Table 5 with means 6 SD. We observe no
significant interaction between sex and age. No signif-
icant result was obtained for the factor age. Some
significant results were obtained between men and
women for the a parameter (P 5 0.0005), the constant
k (P 5 0.0001), time of the maximum (P 5 0.0065), and
slope of formation (P 5 0.0002) for BK, whereas for
des-Arg9-BK, the difference in the means between men
and women was significant only for the constant k (P 5
0.0080).
Table 6 represents the reference intervals calculated
for the different kinetic parameters. In this case to, no
influence of age could be calculated for the synthesis or
the degradation of BK and des-Arg9-BK. Figure 1
shows the mean kinetic profiles of formation and deg-
radation of bradykinin and des-Arg9-bradykinin for
men and women after activation of the contact system,
in the presence of enalaprilat, with glass beads in
normal human plasma.
Comparison Between Exogenous and Endogenous
BK Metabolism
Correlations were calculated between the metabolic
parameters obtained from different experimental ap-
proaches. A highly significant correlation could be mea-
sured between the t1⁄2 of des-Arg9-BK generated from
Table 4. Correlations among APP, ACE activities,
and t1⁄2 BK and des-Arg9-BK in serum of 116 healthy
individuals with and without enalaprilat
BK Des-Arg9-BK
Without
enalaprilat
With
enalaprilat
Without
enalaprilat
With
enalaprilat
APP 20.2433 20.5206 20.6924 20.6840
(P 5 0.0085) (P 5 0.0001) (P 5 0.0001) (P 5 0.0001)
ACE 20.6677
(P 5 0.0001)
Data are Pearson correlation coefficient.
Table 5. Parameters characterizing gamma model
fitted to endogenous measures
Parameter n BK Des-Arg9-BK
a
Total 109 0.7360.20 0.8260.21
Men 40 0.8260.18* 0.8260.20
Women 69 0.6660.19* 0.8260.22
,40 y 72 0.7260.21 0.8060.22
$40 y 37 0.7560.20 0.8660.21
b
Total 109 0.1860.05 0.0760.04
Men 40 0.1860.05 0.0660.03
Women 69 0.1760.06 0.0860.05
,40 y 72 0.1760.05 0.0660.04
$40 y 37 0.1860.06 0.0860.04
k
Total 109 39,853611,335 3,82562,216
Men 40 33,32369,276† 2,94361,265§
Women 69 43,638610,729† 4,33662,485§
,40 y 72 39,755612,066 3,94062,217
$40 y 37 40,04269,913 3,60062,234
Time of maximum,
min
Total 109 461 1669
Men 40 561 1868
Women 69 461 1569
,40 y 72 461 17610
$40 y 37 461 1568
Maximum, pg/100 ml
Total 109 54,161611,945 13,82565,687
Men 40 51,243613,537 13,13065,787
Women 69 55,853610,657 14,22765,631
,40 y 72 53,544611,597 14,25065,760
$40 y 37 55,362612,672 12,99765,525
Area, min zpg z100
ml21
Total 109 783,9496289,160 789,6386810,010
Men 40 747,4406249,324 815,3776590,987
Women 69 805,1136309,689 774,7166917,135
,40 y 72 775,0596267,087 840,7936857,563
$40 y 37 801,2476331,188 690,0926708,894
Slope of t1⁄2 of
Formation
Total 109 25,971610,612 2,38965,604
Men 40 19,88665,418‡ 1,3866631
Women 69 29,498611,297‡ 2,96166,980
,40 y 72 25,890610,566 1,95561,211
$40 y 37 26,126610,395 3,21769,499
Slope of t1⁄2 of
degradation
Total 109 23,20061,108 22746146
Men 40 22,9996982 22126102
Women 69 23,31661,166 23096155
,40 y 72 23,13461,143 22736164
$40 y 37 23,32861,040 22756102
Values are means 6 SD. *P 5 0.0002; †P 5 0.0018; ‡P 5
0.0002; §P 5 0.0080.
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both exogenous (x) and endogenous (y) BK in the pres-
ence of ACE inhibition (y 5 1004.20 1 1.27x, r2 5
0.8269, P , 0.001). Moreover, a highly significant cor-
relation could also be assessed between the t1⁄2 of en-
dogenous des-Arg9-BK (in the presence of enalaprilat)
(y) and APP activity (x) (y 5 6005.46 2 146.43x, r2 5
0.6485, P , 0.001).
DISCUSSION
In this paper, we present for the first time a global
view of kinetic activation of the contact system of
plasma and the characteristics of both BK and des-
Arg9-BK metabolic pathways in the blood of a large
number of healthy people. We used three different
analytic approaches. First, we determined the t1⁄2 of BK
and des-Arg9-BK in the absence and presence of an
ACE inhibitor when BK was added to serum (13).
Second, we measured the enzyme activities of metal-
lopeptidases responsible for the BK metabolism in se-
rum (13). Third, we defined the kinetics of release and
degradation of endogenous BK and des-Arg9-BK when
the contact system of plasma was activated with a
negatively charged surface (23, 33). Although sex in-
fluences the values of several kinetic parameters, no
effect of age could be evidenced.
The first experimental approach extends the results
obtained previously on a limited number of healthy
male individuals (n 5 7) (13). The kinetics of exogenous
kinins studied were performed in serum rather than in
plasma. In fact, we have shown previously that the t1⁄2
of BK, measured in plasma anticoagulated with ci-
trate, does not follow first-order kinetics, although the
Table 6. Distribution of parameters of the model
n BK des-Arg9-BK
a
Total 109 0.41–1.12 0.50–1.27
Men 40 0.51–1.23
Women 69 0.38–1.06
,40 y 72
$40 y 37
b
Total 109 0.102–0.306 0.017–0.166
Men 40
Women 69
,40 y 72
$40 y 37
k
Total 109 18,321–63,796 1,342–8,876
Men 40 12,931–50,506
Women 69 23,838–66,836
,40 y 72
$40 y 37
Time of maximum,
min
Total 109 2.71–6.86 4.52–40.42
Men 40 3.52–6.87
Women 69 2.67–6.57
,40 y 72
$40 y 37
Maximum
Total 109 30,518–77,727 601–30,649
Men 40
Women 69
,40 y 72
$40 y 37
Area, min zpg z100
ml21
Total 109 360,760–1,454,347 121,004–3,414,760
Men 40
Women 69
,40 y 72
$40 y 37
Slope formation
Total 109 10,346–58,304 745–4,757
Men 40 9,835–28,990
Women 69 14,773–60,147
,40 y 72
$40 y 37
Slope degradation
Total 109 2539 to 21,495 2528 to 2106
Men 40
Women 69
,40 y 72
$40 y 37
Data are reference intervals (2.5–97.5% of each distribution).
Fig. 1. Mean kinetic profiles of formation and degradation of brady-
kinin (A) and des-Arg9-bradykinin (B) for men and women after
activation of the contact system, in the presence of enalaprilat, with
glass beads in normal human plasma. Kinetic profile for bradykinin
shows a difference between men (n 5 40) and women (n 5 69) in the
formation part of the curve, whereas for des-Arg9-bradykinin a
difference is observed at the degradation level.
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t1⁄2 of BK and des-Arg9-BK is similar in both conditions.
With this approach (13), we demonstrated that BK t1⁄2
is significantly higher in women than in men. When
sera were preincubated with enalaprilat, this differ-
ence was not further observed. In the case of des-Arg9-
BK, the t1⁄2 was much higher than that of BK. The
preincubation of serum with an ACE inhibitor also
increased des-Arg9-BK t1⁄2, but the potentiating effect
was lower than for BK. These results confirm our
previous observations showing that ACE, the main
degrading pathway of BK, is a secondary pathway for
des-Arg9-BK (13). Under the same conditions, kininase
I is a minor pathway, but its importance increases
when ACE is inhibited.
We have previously used this approach to define the
metabolism of exogenous kinins in the sera of patients
who presented an acute side effect when treated with
an ACE inhibitor. In patients who manifested HSR
while on an ACE inhibitor and hemodialysis with a
negatively charged membrane, we found a significantly
higher t1⁄2 of des-Arg9-BK but not of BK compared with
patients who had never developed such an acute side
effect while dialyzed under the same conditions (6).
This difference affecting des-Arg9-BK degradation was
exaggerated when serum samples were preincubated
with an ACE inhibitor. A similar anomaly affecting
des-Arg9-BK metabolism could be observed in patients
who presented SHR while treated with an ACE inhib-
itor and transfused with platelets or red blood cells
that had been depleted of leukocytes by passage
through a negatively charged membrane (11). When
applied to the sera of patients who manifested AE
associated with an ACE inhibitor, we could not, how-
ever, find a difference compared with healthy sub-
jects (7).
We have reported previously that BK is mainly me-
tabolized in serum by three metallopeptidases, ACE,
APP, and kininase I, although des-Arg9-BK in its turn
is degraded by only ACE and APP. In this study, we
observed lower ACE activity in women. This finding
must be related to the BK t1⁄2 and the calculated rela-
tive participation of ACE. Recently, it was reported
that estrogen treatment modulates ACE mRNA con-
centration in rat tissues, with a resultant attenuation
of tissue and serum ACE activity (17). Moreover, a
decreased plasma level of ACE activity with a concom-
itant increase of plasma BK was observed in both
hypertensive and normotensive postmenopausal
women under hormone replacement therapy (39).
We have previously shown that APP is significantly
lower in patients with a history of HSR (HSR1) dia-
lyzed with a negatively charged membrane when com-
pared with patients who did not present such reactions
(HSR2), these activities being negatively correlated
with des-Arg9-BK t1⁄2 calculated in the presence of an
ACE inhibitor (6). In this study, we confirmed the
highly significant correlation between both parame-
ters. Moreover, the higher activity of APP in women
can be related to the fact that this metallopeptidase is
encoded by chromosome X (38, 41).
Activation of plasma by its contact with a negatively
charged surface is classically used to trigger the intrin-
sic coagulation pathway (23). An early study measured
the kinetic release and degradation of BK (19) but did
not consider des-Arg9-BK metabolism. This new ap-
proach, which reflects the activation of HK by plasma
kallikrein, is important for at least two reasons. First,
it allows a more physiological understanding of the
plasma metabolism of BK and des-Arg9-BK than that
obtained by spiking serum with exogenous BK, even at
a nanomolar concentration. Second, it could allow new
insights into the role of in vivo activation of the contact
system in different pathophysiological conditions
where its involvement is suspected (14, 27). To do that
we activated the plasma with glass beads, a process
that has been reported to be efficient in triggering the
contact system (23). This activation is obtained in the
presence of an ACE inhibitor to increase the impor-
tance of the BK/des-Arg9-BK metabolic pathway. The
development of a mathematical model permits the
analysis of different parameters characterizing the
genesis of both endogenous B1 and B2 agonists and
their degradation. We could observe, for the first time,
that men and women differ in their formation of BK,
whereas a difference is seen in the degradation of
des-Arg9-BK. Further studies are necessary to explore
the sex difference in the generation of endogenous BK.
The difference cannot be attributed to the concentra-
tion of HK. In fact, in a precedent study (1), Adam et al.
could find no evident difference between men and
women for the precursor of BK, and they could not
detect a significant difference of plasma prekallikrein
activity when assessed by a chromogenic substrate in
men and women (2).
In comparison to the results obtained for the exoge-
nous peptide, the t1⁄2 of endogenous des-Arg9-BK could
be correlated not only with the t1⁄2 of des-Arg9-BK
generated from exogenous BK but also with APP activ-
ity. These observations show for the first time that this
metallopeptidase and its sex-related differences are
physiologically relevant in the degradation of the en-
dogenous B1 agonist.
The results presented in this study constitute a new
basis for further investigations not only of the BK and
des-Arg9-BK metabolic pathways but also of the con-
tact system of plasma. First, studies will be needed in
the future to examine the pharmacogenetic aspect of
side effects of ACE inhibitors. In fact, because APP has
been shown to be encoded by chromosome X (38, 41)
and because we have previously measured a decreased
activity of that enzyme in HSR1 patients (6), we are
working on defining the genetic aspects of this side
effect. These investigations will also be extended to
SHR. For ACE inhibitor-associated AE, in which we
previously failed to evidence an anomaly of the exoge-
nous BK/des-Arg9-BK metabolic pathways, we cannot
exclude a dissociation between the metabolism of ex-
ogenous and that of endogenous BK, BK being gener-
ated and degraded locally. The kinetic measurement of
endogenous BK and of des-Arg9-BK during plasma
activation will be particularly interesting in this latter
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case. Finally, the kinetic release of BK from endoge-
nous HK and its metabolism to des-Arg9-BK could open
a new area of research to reassess the role of endoge-
nous kinins in different pathological states (14, 27),
where activation of the contact system of plasma has
been documented.
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